New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Pfizer Inc.

PFE

Healthcare Drug Manufacturers General

Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024.

Revenue
−0.43%
EPS
−9.68%
Free cash flow
+20.0%
Total debt
+1.55%

Quarter to September 2026, against a year earlier

27.60 0.03 +0.11%
Market cap
$158.2B
P/E
38.8×
Fwd P/E FY26e
18.7×
Dividend yield
6.24%
F-score
6/9
ROIC
6.19%
Net debt / EBITDA
2.5×
Payout ratio
2.5×

Pfizer Inc. 10-Q filed Aug 5, 2025

Fiscal Q2 2025 · Period ended Jun 29, 2025 · Filed · accepted 7:16 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 5, 2025: 19 added · 12 removed · 67 modified; 5 with only figures updated

  1. Modified · Realigning Our Cost Base Program

    Our Business Development Initiatives––We are committed to strategically capitalizing on growth opportunities, primarily by advancing our own product pipeline and maximizing the value of our existing products, but also through various business development activities. For a description of the more significant recent transactions through February 27, 2025, the filing date of our 2024 Form 10-K, see Note 2 in our 2024 Form 10-K. See Note 2 and the following for significant recent activities.: